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Abstract
Background: Human cancer is caused by the accumulation of somatic mutations in tumor suppressors and
oncogenes within the genome. In the case of oncogenes, recent theory suggests that there are only a few key “driver”
mutations responsible for tumorigenesis. As there have been significant pharmacological successes in developing
drugs that treat cancers that carry these driver mutations, several methods that rely on mutational clustering have
been developed to identify them. However, these methods consider proteins as a single strand without taking their
spatial structures into account. We propose an extension to current methodology that incorporates protein tertiary
structure in order to increase our power when identifying mutation clustering.
Results: We have developed iPAC (identification of Protein Amino acid Clustering), an algorithm that identifies
non-random somatic mutations in proteins while taking into account the three dimensional protein structure. By
using the tertiary information, we are able to detect both novel clusters in proteins that are known to exhibit mutation
clustering as well as identify clusters in proteins without evidence of clustering based on existing methods. For
example, by combining the data in the Protein Data Bank (PDB) and the Catalogue of Somatic Mutations in Cancer,
our algorithm identifies new mutational clusters in well known cancer proteins such as KRAS and PI3KCα. Further, by
utilizing the tertiary structure, our algorithm also identifies clusters in EGFR, EIF2AK2, and other proteins that are not
identified by current methodology. The R package is available at: http://www.bioconductor.org/packages/2.12/bioc/
html/iPAC.html.
Conclusion: Our algorithm extends the current methodology to identify oncogenic activating driver mutations by
utilizing tertiary protein structure when identifying nonrandom somatic residue mutation clusters.
Background
Cancer is one of the most widespread and heteroge-
neous diseases imposing a huge toll on patients, rela-
tives, friends, and society. However, at its most basic, it
is a genetic disease that is caused by the accumulation
of somatic mutations in oncogenes and tumor suppres-
sors [1]. While mutations in tumor suppressors tend to
down-regulate the activity of genes that prevent can-
cer, mutations in proto-oncongenes either up-regulate
or deregulate the activities of the resulting proteins. So
far, pharmacological intervention has shown to be more
successful at inhibiting activating oncogenes than restor-
ing tumor suppressing gene function. Coupled with the
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idea of “oncogene addiction”, that many cancers rely on
mutations in a small subset of key genes to be able to
continue their uncontrolled growth while the remainder
of the mutations constitute passenger mutations [2,3], the
problem of identifying activating oncogenicmutations has
received great attention in cancer research.
Recently, several studies have shown support for the
hypothesis that activating somatic mutations tend to clus-
ter in protein kinases [2,4,5]. Further, as observed by
[6], mutational clusters might provide further information
regarding where to look for activatingmutations, reducing
the driver mutation search space needed to be analyzed.
Moreover, mutational clusters that lead to either bene-
ficial or detrimental phenotypic changes may point to
regions that are under positive or directional selection as
well as regions that are functionally significant and thus
can be targeted by protein engineering [7].
So far, several methods based upon the number of muta-
tions in a specific region have been developed to detect
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potential driver oncogenic mutations as well as natu-
rally selected regions. One common method hypothesizes
that driver mutations have a higher non-synonymous
mutation rate as compared to the background mutation
rate [5,8]. Further, one can look at the ratio of non-
synonymous (Ka) to synonymous (Ks) changes per site,
Ka
Ks [9]. A criterion for selection is then to check if
Ka
Ks > 1,
based on the hypothesis that the benchmark neutral rate
of nucleotide substitution is exceeded when positive selec-
tion also contributes to the substitution process. Similarly,
[10] proposes a hypothesis that driver mutations have a
larger mutational rate than the background mutational
rate after gene length normalization.
While the approaches mentioned above have had some
success in detecting positive selection and/or identifying
driver mutations, they nevertheless have several short-
comings. First, many of them are dependent on calculat-
ing the disparity in non-synonymous versus synonymous
mutations but do not recognize that selection often occurs
on very small sections of the gene and thusmight fail when
averaged over the entirety of the gene length. Second, the
methods described above [9,10] do not make any attempt
to distinguish between activating and non-activating non-
synonymous mutations.
In addition to the approaches described above, some
researchers have focused on creating classifiers in order
to determine mutation status. As described in [11], these
algorithms employ a variety of machine learning tech-
niques, such as Random Forests [12] and Support Vector
Machines [13], to calculate a score for each mutation.
These scores are typically calculated using a variety of
information such as measures of evolutionary conserva-
tion as well as physico-chemical properties such as size
and polarity of substituted and original residues as well as
surface accessibility. These scores are then used to clas-
sify the mutation. For example, PolyPhen-2 [14] predicts
whether a missense mutation is damaging while CHASM
[15] attempts to discriminate between driver and passen-
ger mutations. While several of these models have had
significant success in classifying the mutation, they all
require large and well annotated data sets in order to first
train the machine learning classifier and then apply the
resulting rule set.
Recently, [6] developed Non-Random Mutational Clus-
tering (NMC) to identify potential activating mutations
by hypothesizing that, in the absence of heretofore known
mutational hotspots, a mutational cluster is indicative of
selection for an activating driver mutation since only a
small number of precise mutations can activate a pro-
tein [4,5]. By looking at the order statistics and assuming
that the locations of amino acid mutations follow a uni-
form distribution when the protein is considered in linear
form under the null hypothesis, they identify clusters
by calculating whether any two pair-wise mutations are
closer together on the line than expected by chance alone.
Despite its success, one limitation of the NMC method
is that the proteins are treated as a linear sequence with-
out considering the three dimensional structures of the
proteins.
In this work, we extend the NMC methodology to
account for tertiary protein structure. This enables the
identification of mutational clusters that are relatively
far away in linear space but relatively close together in
3D space. We proceed to show that our methodology is
effective in identifying novel mutational clusters that are
missed by NMC in key cancer proteins such as KRAS
and PIK3Cα. Unlike NMC, iPAC is also able to identify
the EGFR and EIF2AK2 proteins as containing mutational
clustering as well. We also show that many of the clusters
identified by iPAC are predicted to be deleterious by well
known machine learning algorithms such as Polyphen-2
[14]. However, iPAC has the distinct advantage of requir-
ing only the mutational positions and tertiary structure
which allows its application to novel mutations and struc-
tures for which extensive information and literature is not
yet available. Finally, we also show that for a large per-
centage of protein structures, the tertiary structure leads
to a net reduction in mutational clusters found, thus pre-
senting a simplified clustering mutational landscape. Ulti-
mately, by providing a refined picture of the mutational
clustering, we are are able to provide a more accurate rep-
resentation of where potential activating mutations may
reside within the protein.
Methods
Our method, named iPAC, uses a 4 step approach to find-
ing mutational clusters. First, mutational and positional
data are obtained from the COSMIC [16] and PDB [17]
databases (described in Sections “Obtaining mutational
data” and “Obtaining the 3D structural data”, respectively).
The mutational and positional information is then recon-
ciled to allow a single numerical reference to identify the
same physical amino acid in both databases (Section “Rec-
onciling the structural and mutational data”). Next, Mul-
tiDimensional Scaling (MDS) [18] is used to map the
protein structure from 3D to 1D space while preserving, as
best as possible, all pairwise three dimensional distances
between amino acids for a given protein (Section “Mul-
tidimensional scaling”). The NMC algorithm is then run
on the remapped amino acids to find mutational clusters
(Section “NMC”). Finally, the clusters are mapped back
into the original protein space and reported back to the
user. In the following subsections we discuss each of these
steps in detail.
Obtainingmutational data
Mutational data were obtained from the COSMIC
database (version 58) via ftp.sanger.ac.uk/pub/CGP/cosmic
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and implemented using Oracle. In order to justify the
assumption that amino acids follow a uniform distribu-
tion of mutation, only mutations that were found through
whole gene screens were included. Further, we only used
missense mutations that belonged to two categories: 1)
“Confirmed somatic variant” or 2) “Reported in another
cancer sample as somatic”. All nonsense and synony-
mous mutations as well as mutations that had dif-
ferent somatic status categories were excluded. Fur-
ther, as multiple studies can report mutational data
from the same cell line, mutational redundancies were
removed to avoid double counting. See “Additional file 1:
Cosmic Query” for the SQL code and schema used to
generate the data. Finally, in order to match mutational
data with structural data, only the proteins for which a
UniProt Accession Number [19] was available were kept.
This resulted in 777 unique proteins.
Obtaining the 3D structural data
The protein structural data were obtained from the PDB
database via http://www.pdb.org. As one protein can have
several structures, for each of the 777 proteins described
above, all the structures with a matching UniProt Acces-
sion Number were obtained. If a specific structure had
more than one polypeptide chain with a matching amino
acid sequence in UniProt, the first matching chain listed
was used (typically chain A). For proteins where the reso-
lution was sufficiently high enough to provide more than
one alternative conformation for a specific amino acid side
chain, only the first conformation listed in the file was
used. Once the appropriate side chain and conformation
was selected, the (x, y, z) coordinates of all the α-carbon
atoms were extracted and used to represent the 3D back-
bone structure of the protein. In all, this process resulted
in 1,904 structures. See “Additional file 2: Structure Files”
for a full listing of the structures and side chains used for
each protein considered.
Reconciling the structural andmutational data
Due to a different numbering system of the amino acids
employed by the PDB and COSMIC databases, an align-
ment needed to be performed in order to reference the
same residue numerically in both databases. Two meth-
ods in the iPAC package were designed to reconcile these
differences, one based on pairwise alignment [20] and the
other based on a numerical reconstruction from the struc-
tural data obtained from the PDB. As there are often sig-
nificant technical difficulties for such a reconstruction, for
the rest of this paper, unless specifically noted, pairwise
alignment was used to reconcile these elements. Please
see the documentation in the iPAC package for a full
description of these twomethods. Successful alignment of
mutational and positional data occurred on 140 proteins
which corresponded to 1100 unique structure/side-chain
combinations and 667 unique residue positions contain-
ing 1,434 total mutations. We note that for any given
structure/side-chain combination, if there is no positional
data for a specific residue, the mutational data for that
residue is not used. Please see “Additional file 2: Structure
Files” for a full description.
Multidimensional scaling
As the underlying clustering algorithm is dependent upon
the construction of order statistics, we used MDS [18] to
remap the amino acids into one dimensional space while
preserving (as best as possible) the pairwise distances
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the MDS algorithm maps each δi,j into a corresponding
distance di,j(X) on a new m-dimensional metric space
X. Formally, for a specific representation function, f :
δi,j → di,j(X), we have that the original dissimilarities
are preserved in X, specifically, f (δi,j) = di,j(X). Here,
f can be either fully defined or chosen from a specified
class of functions and is employed to handle the case
when the proximity measures come from a space that is
not necessarily a true metric space. Further, as it is not
always possible to preserve the exact distance (for exam-
ple, due to sampling effects, measurement precision or
loss of dimensionality), rather than insist on f (δi,j) =
di,j(X), the MDS framework is typically set up such that
f (δi,j) ≈ di,j(X). Thus, by minimizing a badness-of-fit
measure called raw stress = σr = ∑i,j[ f (δi,j) − di,j(x)]2,
we identify the x1, ..., xn, that preserve our distances in
the new metric space X. However, raw Stress by itself is
not always informative as it is subject to distortion by the
choice of units used. For instance, if the scale used to mea-
sure changes by a factor of 100, the raw stress will change





i,j[ f (δi,j) − di,j(X)]2∑
i,j d2i,j(X)
(1)
and is not subject to unit distortion, will be minimized
instead.
For the purposes of this paper, the dissimilarity matrix is
simply equal to pair-wise distance between any two amino
acids in the protein. Specifically, the distance between
residues i and j, denoted δi,j, is taken to be the Euclidean
distance between their respective α-carbon atoms. As
Euclidean space is a proper metric space, from now on
we assume that f is the identity function. Further, as we
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require units along the line in order to calculate order
statistics, the MDS algorithm will be applied such that we
find x1, ..., xn ∈ R1. Thus, theMDS algorithm finds scalars
x1, ..., xn such that |xi − xj| ≈ δi,j, for any two pairwise
amino acids i and j in the protein. We present an example
whenMDS is applied to the 3GFT structure of KRAS [21]
in Figures 1 and 2 below.
NMC
We employed the NMC algorithm [6] to find the muta-
tional clusters in one dimensional space. Specifically, con-
sider a protein with N amino acids and that each amino
acid has a uniform probability of 1N of mutation. Given
m samples and n mutations, we are able to calculate the
order statistics for every mutation (see Figure 3). Two
mutations X(i) and X(k) are then defined to be clustered if,
Pr(Cki = X(k) − X(i)) ≤ α. This probability is then calcu-
lated for every pair of mutations and adjusted for multiple
comparisons using either the Benjamini-Hochberg (BH)
adjustment [22] or the Bonferroni adjustment [23,24]. For
the analyses performed in this paper, the more conserva-
tive Bonferroni adjustment was used. Finally, it is impor-
tant to note that the structural information obtained for
each protein often does not include positional information
on every amino acid within the protein.We removed these
“missing” amino acids from the protein before running the
NMC clustering algorithm so that we can compare iPAC
and NMC on an equal basis.
[6] derive closed form solutions to calculate the
Pr(Cki = c) for c ∈ {0, 1, ...,N − 1}. However, as this
becomes computationally inefficient, they suggest divid-
ing Cki by N and assuming a continuous uniform distribu-
tion on (0, 1). They then show that in the limit, the CDF
becomes as follows:
























Figure 1 KRAS α-carbons in 3D Space.































(k − i − 1)! (i + n− k)!y
k−i−1(1 − y)i+n−kdy
= Pr(Beta(k − i, i+ n − k + 1) ≤ c)
(2)
Thus, via Equation (2), we can directly calculate if
two mutations are closer together than by chance alone
quickly and efficiently. For a given structure, a cluster was
considered to be significant using an α-level of 0.05 and
the Bonferroni adjustment. Specifically, the p-value of the



















Figure 3 An example of constructing the order statistics.
Suppose we had 3 samples of a protein that is N amino acids long. If
amino acid i has a “*” above it, that indicates that the amino acid for
that sample had a non-synonymous missense mutation. The samples
are then collapsed together and the number of mutations for each
residue is shown above the box on the right. These counts form the
order statistics. The first mutation is on residue 2 (X(1) = 2), the next 3
mutations are on residue 3 (X(2) = X(3) = X(4) = 3) , the next
mutation is on residue 5 (X(5) = 5) and the last 2 mutations are on
residue 6 (X(6) = X(7) = 6).
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Multiple comparison adjustment for structures
In addition to the Bonferroni multiple comparison adjust-
ment done by the NMC method, an adjustment is also
required to account for testing multiple structures per
protein. Since the structures for a given protein could be
quite similar and thus lead to similar clustering results,
a second Bonferroni adjustment would be too conserva-
tive. Instead, a combined Bonferroni-FDR approach was
performed as follows. First, for a given protein, the NMC
reported p-value for a given cluster was multiplied by
n(n−1)
2 , to calculate P∗. Thus, on a per-protein level, P∗
represents the inverse Bonferroni adjustment performed
by the NMC algorithm and thus allowed us to compare
each cluster’s P∗ to an α-level of 0.05 to determine sig-
nificance. To account for all the structures analyzed, we
computed a rough FDR (rFDR) [25] which approximates
the standard FDRmethod for a large number of positively
correlated or independent tests. Under this approach, we
estimate the expected value of α over all k tests and then
use that as the significance threshold. The expected value
α can be approximated by:
rFDR = α ∗ k + 12k
where k is the total number of structures. In the case
of the 1100 structures analyzed in this study, rFDR ≈
0.02502. Finally, any clusters for which P∗ ≤ 0.02502
was deemed to be significant. For the rest of this
paper, with the exception of Table 1, we only report
the p-value to avoid confusion. Nevertheless, each clus-
ter presented in Section “Results and discussion” is in
fact significant after adjusting for structural multiple
comparisons.
Results and discussion
Using the iPAC package, 215 of the total 1100 struc-
tures analyzed were found to have significant clustering.
When comparing iPAC with the original NMC method,
out of the 140 proteins analyzed, both iPAC and NMC
identified 8 proteins that contained significant clusters.
However, iPAC also identified 3 new proteins as well,
specifically EGFR, EIF2AK2 and HAO1. These 3 new
proteins correspond to 10 of the 215 structures found
to have clustering. iPAC also found structure 2ENQ for
the protein PIK3CA to contain a significant cluster while
NMC did not. The 8 proteins identified by both algo-
rithms correspond to the remaining 204 structures. There
were no proteins that were identified by NMC but were
subsequently missed by the iPAC algorithm. Please see
“Additional file 3: Results Summary” for a full listing of
which structures and which proteins were found to be
significant.
As can be seen from Figure 4, approximately 70% of
all the structures found to have significant clustering
differed in the amount of clusters identified when com-
paring iPAC vs NMC. This leads one to believe that in
some cases, consideration of the tertiary structure iden-
tifies additional clusters while in other cases, clusters are
able to be removed, offering a simplified view of the
mutational information. While it is outside the scope of
this paper to consider every one of the 215 structures
with clustering, we present three representative cases
where integration of the tertiary protein structure into
the analysis had a significant effect: 1) identification of
mutation clustering in a protein that would otherwise
be missed, 2) identification of new mutation clusters in
a protein that was detected using the NMC methodol-
ogy, and 3) reduction of the total mutational clusters in
a protein that was detected using the NMC methodol-
ogy. We also note, as can be seen in Table 1, that the
p-value found for the most significant cluster is similar on
the protein level. Proteins that had very significant clus-
tering, such as KRAS and TP53, remain very significant
when the tertiary structure is incorporated. Proteins that
were less significant, such as IDE and AKT1, remain so
as well.
Table 1 A comparison of themost significant iPAC and NMC p-values from the 8 proteins thatwere picked up by both
algorithms
iPAC NMC
Protein P-value P* P-value P*
KRAS 6.17 E-185 6.35 E-181 4.39 E-233 4.52 E-229
TP53 5.23 E-128 6.11 E-123 4.37 E-086 5.30 E-81
BRAF 3.73 E-130 1.01 E-126 3.84 E-130 1.04 E-126
PIK3CA 8.20 E-084 3.58 E-80 8.20 E-084 3.58 E-80
NRAS 5.38 E-026 6.46 E-24 8.26 E-029 9.91 E-27
HRAS 1.23 E-010 5.54 E-09 5.61 E-010 8.42 E-09
AKT1 1.18 E-005 7.08 E-05 2.47 E-005 7.41 E-05
IDE 2.20 E-005 6.60 E-05 1.56 E-003 4.67 E-03
P* is calculated as described in Section “Multiple comparison adjustment for structures”.
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Figure 4 A comparison of NMC and iPAC over all the structures
that were found to be significant. The number of structures in each
category is shown along with the percentage.
We note that 9 out of the 11 proteins that were found
significant by iPAC had theirmost significant cluster over-
lap a binding site, proton acceptor site or kinase domain.
Of the remaining 2 proteins, the most significant clus-
ter for PIK3CA overlapped amino acid 1047, which has
been shown to ease the entrance of substrates and hence
potentially increase the substrate turnover rate, a typi-
cal oncogenic behavior [26]. For a detailed per protein
description, please see “Additional file 4: Relevant Sites”.
Finally, we validated the performance of iPAC using two
popular machine learning algorithms, PolyPhen-2 [14]
and CHASM [15]. First, this validation must be consid-
ered in light of the fact that these algorithms require a
much more extensive set of information than iPAC. Nev-
ertheless, over 98% of the amino acids that occurred in
significant mutation clusters were also identified as signif-
icant (with a FDR of ≤ 20%) by Polyphen-2 and CHASM.
For full details, please see “Additional file 5: Performance
Validation”.
iPAC finds novel proteins
As discussed Section “Results and discussion”, three new
proteins were identified by iPAC that were missed when
tertiary structures are not accounted for. The EGFR pro-
tein, a cell-surface receptor for epidermal growth factor
family ligands [27], is perhaps the most well known and
has been found in a wide array of cancers such as lung [28],
anal [29] and glioblastoma multiforme [30]. Although
seven EGFR structures were identified by iPAC to contain
significant clustering, we will concentrate on the 2GS7
structure [31] as it showed the most significant cluster-
ing. As seen in Table 2, three significant clusters were
found with cluster 3 being being a sub-cluster of cluster 1.
Figure 5, shows the orientation of these clusters in three
dimensional space.
Overall, all the statistically significant clusters found
deal with lung cancer pathology and an increase in kinase
activity. The two mutations in cluster 2, G719S and T751I
are both found in lung cancer with the first mutation
Table 2 The threemost significant clusters found in EGFR
for the 2GS7 structure
Cluster Start End Muts. in cluster P-Value
1 751 858 4 1.35E-04
2 719 751 2 2.41E-03
3 790 858 2 2.82E-03
responsible for strongly increased kinase activity [32-34]
and the second found in erlotinib responsive non small
cell lung cancer patients (NSCLC) [35,36], respectively.
Cluster 3 contains two mutations, T790M and L858R,
both of which have been found in lung cancer and are
known for increased kinase activity as well [32-34,37].
Finally, cluster 1 is comprised of clusters 2 and 3, with an
additional mutation S768I which potentially shows a pos-
itive clinical response to Getfinib in NSCLC patients [38].
It is interesting to note that both clusters 1 and 2, that
are identified via statistical analysis, contain mutations
that have been found to benefit from pharmacological
intervention. Had the tertiary structure of EGFR not been
taken into account, these clusters would not have been
identified by the NMC algorithm. When the protein is
viewed linearly, the mutations occur too far away from
each other to result in statistically significant p-values.
iPAC finds additional clusters
One example where iPAC finds additional clusters is in
the KRAS protein when analyzing the 3GFT structurea
[21]. KRAS, part of the RAS set of of proteins which are
involved in a large number of signaling cascades, is one of
Figure 5 The EGFR Structure (PDB ID 2GS7)(structure color coded
by region: 1) (cluster 1 - light blue and yellow, 2) (cluster 2 - blue
and 3) cluster 3 - yellow. The boundary α-carbon amino acids of
719, 751, 768, 790 and 858 are shown as purple spheres (see Table 2
for details of each cluster).
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the most studied cancer oncogenes with activating muta-
tions in approximately 17-25% of all human cancers [39].
While both NMC and iPAC identified many of the same
clusters such as amino acids 12-13, 12-61 and 12-146,
iPAC identified several novel clusters as well, specifically
amino acids 61-117 and 117-146. We note that both algo-
rithms specifically identify a cluster between residues 12
and 146, and given that we only have positional data for
167 residues, this signifies that there is one large clus-
ter that covers ≈ 80% of all the available amino acids.
However, combined with the two novel clusters identified
by iPAC, we are able to partition the protein into three
distinct regions 1) 12-61, 2) 61-117 and 3) 117-146 that
cover 30%, 34% and 18% of the protein respectively (see
Figure 6).
We also ran NMC and iPAC on each region separately
to consider how the clustering results would be affected.
As can be seen from Table 3, failure to account for the ter-
tiary protein structure resulted in region 3 no longer being
detected and region 1 losing significance by over ninety
orders of magnitude.
Further, while somatic mutations in region 12-61 have
been found in many cancers such as colorectal, lung, pan-
creatic and bladder [8,33,40-43], somatic mutations at
amino acids 61, 117 and 146 have primarily been found
in lung and colorectal carcinomas. Even more specifically,
mutations at amino acids 117 and 146 (K → N and A
→ T, respectively) deal mostly with colorectal cancer [8].
Figure 6 The 3GFT structure color coded by region: amino acids
13-60 are light blue, 62-116 are red and 118-145 are yellow. The
boundary α-carbon amino acids of 12,61,117 and 146 are shown as
purple spheres (see Table 3 for details of each cluster).




1) 12-61 1.37E-11 3.36E-105
2) 61-117 - -
3) 117-146 - 3.35E-12
2&3) 61 - 146 - 3.31E-05
A “-” signifies that the region was not found to be significant.
Thus, by taking into account the tertiary structure, the
clusters identified by iPAC subdivide the protein along
pathological lines.
iPAC finds fewer clusters than NMC
Of the 215 structures found to contain significant clus-
tering, 86 structures were identified where iPAC found
fewer structures than NMC. Three of these structures
correspond to BRAF, 31 correspond to HRAS and 52 cor-
respond to TP53. Here, we consider structure 3TV4 [44]
for the BRAF protein as it contains the most significant
cluster found by both iPAC and NMC. For this protein,
it is well known that amino acid 600 is one of the most
highly mutated residues. In our dataset, 60 of the 76 total
mutations that fulfilled the requirements described in
Section “Obtaining mutational data” occurred on amino
acid 600. As expected, the most significant “cluster” is
located solely on that amino acid, with an iPAC p-value
of 3.73 × 10−130 and an NMC p-value of 3.84 × 10−130.
However, in total, iPAC identifies 9 clusters for this struc-
ture while NMC identifies 19, with the differences shown
in Tables 4 and 5.
While it is outside the scope of this paper to con-
sider all the differences between Table 4 and 5, we would
Table 4 The significant clusters found by both and NMC
Clusters found by both NMC and iPAC
P-value
Start End # Muts. iPAC NMC
600 600 60 3.73 E-130 3.84 E-130
469 600 70 9.76 E-122 5.63 E-16
600 601 62 3.10 E-79 1.35 E-117
597 600 62 4.05 E-77 2.20 E-105
464 600 71 1.25 E-73 1.74 E-16
596 600 64 3.06 E-73 8.28 E-103
581 600 66 1.99 E-51 2.96 E-64
600 671 63 7.78 E-15 3.54 E-28
469 469 4 7.50 E-04 7.50 E-04
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Table 5 The clusters that were not deemed significant by
iPAC but were deemed significant by NMC
Clusters dropped by iPAC
Start End # Muts. NMC Pvalue
597 601 64 8.28 E-103
596 601 66 9.97 E-102
581 601 68 8.73 E-67
596 671 67 1.10 E-31
597 671 65 1.93 E-29
581 671 69 2.22 E-28
464 601 73 7.09 E-19
469 601 72 3.58 E-18
464 671 74 6.01 E-09
469 671 73 2.38 E-08
like to point out that, contrary to iPAC, the NMC algo-
rithm reports the two longest clusters: 1) 464-671 (p-
value = 6.01 × 10−9 ) and 2) 469-671 (p-value = 2.38 ×
10−8). After alignment of the structure as described in
Section “Obtaining the 3D structural data”, we only have
structural information on amino acids 448 - 723. Thus, the
largest cluster detected by NMC covers ≈ 75% of all the
amino acids that we are considering. However, by taking
into account the 3D structure of the protein, these ultra-
long clusters are dropped and the clusters where iPAC and
NMC overlap show 2 distinct areas of the protein, amino
acids 464-600 and 600-671. As expected, as the majority
of mutations occur on amino acid 600, both NMC and
iPAC declare that the “cluster” located at amino acid 600
is highly significant.
Further, as described below, by considering only the
clusters when taking into account the 3D structure
(see Figure 7), the results again tend to fall along
pathological function. After applying the methodology
described in Section “Obtaining mutational data”, the
mutations that were found to be in significant clusters
included G464V, G466V, G469V, G469A, N581S, G596R,
L597V, LV597R, V600E, V600K, K601N and R671Q. As
R671Q was found in only one sample within the COSMIC
database and does not have extensive literature, we will
not include it in further discussion. Taking into account
the 3 most significant clusters picked up by iPAC and
NMC, we now consider the protein in 3 parts: A) Residues
469 - 599, B) Residue 600 and C) Residue 601 (we have
slightly adjusted the clusters displayed in Table 4 to avoid
overlap). The mutations listed that fall with region A, cor-
respond primarily to lung and colorectal cancer [2,45-49].
Region B, which is comprised of only amino acid 600 is
by far the most common mutation with BRAF. This muta-
tion results in constitutive and elevated kinase activity
and has been found in a large range of cancers including
colorectal carcinoma, ovarian serous carcinoma, meta-
static melanoma and pilocytic astrocytoma. Further,
supporting the hypothesis that somatic clusters might
provide pharmacological targets, it has already been
shown that suppression of this cluster in melanoma
causes tumor growth arrest and helps promote apopto-
sis [2,8,48,50-52]. Finally, the K601N mutation in region
C has been found in multiple myeloma patients who also
may benefit from BRAF inhibitors [53].
Conclusion
In this paper, we extended the existing methodology avail-
able to find somatic mutation clustering by utilizing the
information provided in the protein tertiary structure. In
doing so, we showed that we are able to find both new pro-
teins with clustering as well as new clusters in previously
found proteins. We have also shown that by taking into
account 3D structure, we are able to remove clusters that
do not have biological meaning. The method is fast and
robust, with the vast majority of proteins analyzed within
5-10 minutes when executed on a desktop with 8 GB of
DDR3 RAM and an Intel i7 3600k processor running at
a frequency of 3.40 GHZ. Further, as the underlying cal-
culation relies upon the NMC algorithm, a preset fixed
window size is not required which allows for the detec-
tion of clusters of various lengths [6]. We have also shown
that by employing a completely statistical methodology,
we are able to identify mutations that, when suppressed
via pharmacological intervention, may stop further tumor
growth.
This methodology, while an improvement on the NMC
method, still suffers from some limitations. First, the
mutation status of all the amino acids must be determined
Figure 7 The 3TV4 structure color coded by region: 1) Amino
464-600 are light blue 2) Amino Acids 601-671 are orange. The
α-carbons of the mutated amino acids 464, 466, 469, 581, 596, 597,
601 and 671 are shown as purple spheres. Amino acid 600 is colored
red (see Table 4 for details on each cluster).
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although with the advent of high-throughput sequencing,
this will become less of an issue as time progresses. Also,
both hypermutability of genomic locations and unequal
rates of mutagenesis might violate the assumption that
each amino acid has a uniform mutation probability. For
instance, it is well known that hypermutable positions for
both somatic and germline mutations exist. Insertions and
deletions that are typically sequence dependent have been
removed from the analysis and only missense substitu-
tions of single amino acids have been kept in this study
to help reduce such uniformity violations. Similarly, CpG
dinucleotides can have mutational frequency that is ten
times or more that of other dinucleotides [54]. However,
less than 13% of the mutations used to find clustering in
Sections “iPAC finds novel proteins”, “iPAC finds addi-
tional clusters”, and “iPAC finds fewer clusters than NMC”
were in CpG sites. Further, as described by [6], tobacco
smoking preferentially causes transversions in lung can-
cer while the mutational landscape for colorectal cancer
has more transitions [55]. Nevertheless, in the context of
KRAS, the vast majority of mutations occur on amino
acids 12, 13 and 61 for both lung and colorectal cancer.
This suggests that while the mutational spectrum may be
different, it does not have a large effect on the position of
mutations and thus the uniformity assumption. As with
previous studies, while this analysis is influenced by non-
random factors, it nonetheless appears that selection of a
cancer phenotype is the primary cause of clustering.
It should also be noted that while iPAC is designed to
take tertiary structure into account, it is only able to do
so by appealing to theMDSmethodology. Future research
is required in order to relax this restriction to potentially
identify additional clustering results. Next, as we obtained
our mutational data from COSMIC, some tissues types
are over or under-represented. However, such situations
would make our analysis more conservative and the clus-
ters we find even more significant. If different tissue types
host mutations in different parts of the protein, aggre-
gating over all tissue types will result in a larger value
of n while the value of k and i for two specific muta-
tions (as seen in Equation 2) would remain the same. This
results in a higher p-value, implying that clusters that are
found to be significant after collapsing over tissue type
would be even more so if only a specific tissue type was
analyzed.
Finally, as shown in Section ‘Results and discussion”,
iPAC finds fewer clusters for a significant percentage of
the structures analyzed. This reduction in total clusters
can come from two sources: the removal of some amino
acids due to lack of tertiary position information or that
the cluster is no longer found to be significant when 3D
structure is taken into account. The first source, while
already rare will become even more so in the future as
more detailed structural information becomes available.
As for the second source, when a cluster is not identi-
fied under iPAC when compared to NMC, an overlapping
or nearby cluster is typically found (as shown in Tables 4
and 5). For BRAF specifically, there was a total of 3 struc-
tures where iPAC found fewer clusters than NMC. Fur-
ther, every “possibly” or “probably damaging” mutation,
as categorized by PolyPhen-2 [14], was still represented
in at least one cluster in each structure. Thus, in the case
of BRAF, none of the damaging mutations identified by
PolyPhen-2 were lost. For a more detailed analysis, please
see “Additional file 6: Potential Driver Loss”. Ultimately,
further research is required to further reduce the possi-
bility of losing driver mutations while taking into account
tertiary structure.
In conclusion, we present an approach that extends
current methodology to identify mutation clustering by
taking into account protein tertiary structure. We fur-
ther show that by taking into account tertiary structure
we are able to detect clusters that would otherwise be
missed. Next, we demonstrate that for some of the clus-
ters found, pharmacological intervention has already been
successfully applied, further confirming the hypothesis
that mutational clustering might point to activating driver
mutations. As additional protein structures continue to be
solved, iPAC would be able to rapidly perform a statisti-
cal analysis to identify such potential mutations. Finally, as
we gain a better understanding of the tertiary structure of
DNA, this method might also have applications to finding
mutational clustering on the DNA level.
Endnotes
aFor this analysis, we included included mutational and
positional data only on residues 1-167. No 3D positional
information was available in the 3GFT structure on
residues 168-188, and these residues were removed
before the analysis. Further, the structural information
has amino acid 61 as a histidine (isoform 2B for KRAS in
the Uniprot Database) while the COSMIC database has a
glutamine in that position. However, as the substitution
of one amino acid in the structure for another would not
have a significant affect on its spatial orientation and as
amino acid 61 has a large number of somatic mutations,
it was kept in the analysis.
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